Sartorius disclosed revenue pressure tied to U.S. tariff refunds, saying it reduced revenue by €26 million to reflect refunds paid back to customers after Supreme Court action blocked parts of President Donald Trump’s levies. The company’s disclosure makes it one of the first life-science firms to quantify tariff-refund mechanics at the top line. The update highlights the financial spillovers that tariff policy can have even when legal challenges constrain scope, particularly for globally sourced lab and bioprocessing components. Sartorius’ move also signals ongoing uncertainty for budgeting across supply chains amid changing tariff schedules. While the details of how refunds map to specific products and pricing agreements were not fully elaborated in the provided coverage, the accounting adjustment is designed to reflect the change in economic benefit to customers. For biotech-focused manufacturers and procurement teams, the disclosure serves as a reminder that trade policy can flow through both forward pricing and retrospective adjustments.